Stockreport

C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data [Yahoo! Finance]

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy rating on the stock. The price target increase reflects growing conviction follow [Read more]